Literature DB >> 11469536

Interleukin-1beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells.

M Schwemmer1, H Aho, J B Michel.   

Abstract

Two phospholipase A2 (PLA2) isoforms, secretory and cytosolic, have been implicated in inflammation. Secretory type IIA PLA2 (sPLA2-IIA), which hydrolyzes fatty acids bound at the sn-2 position of glycerophospholipids, has been detected universally in a variety of mammalian tissues and cells. The expression of the sPLA2-IIA gene and its extracellular activity were shown to be regulated by different factors such as hypoxia, cytokines and phorbol esters. In the present study, we examined the effects of interleukin-1beta (IL-1beta) on the expression of the 14kDa sPLA2-IIA, determined using reverse transcription polymerase chain reaction and radiometric Escherichia coli enzyme assay in primary cultures of rat endothelial cells and in two different rat endothelial cell lines (SVAREC and RBE4). These experiments revealed that IL-1beta induces sPLA2-IIa gene expression and secretion of the enzyme in endothelial cells in a dose- and time-dependent manner. The cAMP-elevator forskolin did not augment the cytokine-induced elevation of sPLA2-IIa enzyme activity but significantly increased the IL-1beta-stimulated sPLA2-IIa mRNA contents in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469536     DOI: 10.1054/tice.2000.0163

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  6 in total

1.  Divergent mechanisms of action of the inflammatory cytokines interleukin 1-beta and tumour necrosis factor-alpha in mouse cremasteric venules.

Authors:  R E Young; R D Thompson; S Nourshargh
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.

Authors:  Aleksandra A Korotaeva; Elena V Samoilova; Aleksander I Kaminny; Aleksandra A Pirkova; Therese J Resink; Paul Erne; Nina V Prokazova; Vsevolod A Tkachuk; Evgeny I Chazov
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

3.  Marine phospholipids--a promising new dietary approach to tumor-associated weight loss.

Authors:  Lenka A Taylor; Lars Pletschen; Jann Arends; Clemens Unger; Ulrich Massing
Journal:  Support Care Cancer       Date:  2009-04-29       Impact factor: 3.603

4.  Regulatory effects of the JAK3/STAT1 pathway on the release of secreted phospholipase A₂-IIA in microvascular endothelial cells of the injured brain.

Authors:  Guansong Wang; Pin Qian; Zhi Xu; Jiqiang Zhang; Yaoli Wang; Saiyu Cheng; Wenqin Cai; Guisheng Qian; Changzheng Wang; Mark A Decoster
Journal:  J Neuroinflammation       Date:  2012-07-12       Impact factor: 8.322

5.  Changes in Plasma Acylcarnitine and Lysophosphatidylcholine Levels Following a High-Fructose Diet: A Targeted Metabolomics Study in Healthy Women.

Authors:  Anita Gonzalez-Granda; Antje Damms-Machado; Maryam Basrai; Stephan C Bischoff
Journal:  Nutrients       Date:  2018-09-06       Impact factor: 5.717

6.  Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI.

Authors:  Changqing Sun; Wuyang Zheng; Ling Liang; Zuheng Liu; Wenchao Sun; Rong Tang
Journal:  J Interv Cardiol       Date:  2021-09-07       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.